189 results on '"Moreau, Thomas"'
Search Results
152. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells
- Author
-
Moreau, Thomas, primary, Bardin, Florence, additional, Imbert, Jean, additional, Chabannon, Christian, additional, and Tonnelle, Cécile, additional
- Published
- 2004
- Full Text
- View/download PDF
153. West Nile virus on the rise.
- Author
-
Ogunfiditimi, Folusho, Boissonneault, Gilbert, Brenneman, Anthony E., Essary, Alison C., Léger, Marie-Michèle, and Moreau, Thomas
- Published
- 2013
154. A rapid and reversible colorimetric assay for the characterization of aminated solid surfaces.
- Author
-
Gaëlle, Coussot, Perrin, Catherine, Moreau, Thomas, Dobrijevic, Michel, Postollec, Aurélie Le, and Vandenabeele-Trambouze, Odile
- Subjects
SOLIDS ,AMINES ,AMINATION ,POLYSTYRENE ,COLORIMETRIC analysis - Abstract
The covalent immobilization of synthetic or natural macromolecular compounds containing amino groups onto polystyrene (PS) solid surfaces is of great interest in diagnostic applications. A sensitive assay allowing the determination of reactive end groups is therefore a powerful tool for predicting the performance of the active surface. Recently, we reported the use of the Coomassie brilliant blue (CBB) colorimetric reagent to quantify protonated groups (N) in linear and dendritic structures in solution (Coussot et al., Polym Int 58(5):511-518, ). In this work, a simple method using CBB dye for the characterization of PS aminated solid surfaces is developed. The proposed amino density estimation by colorimetric assay (ADECA) method is based on the reversible complexation of the dye with the N groups on solid surfaces. The assay measures the released dye thanks to the use of a unique sodium carbonate-methanol buffer. Thereby, for the first time, the same surface can be used for characterization and for further coupling applications. A surface density of four N groups per square nanometer can be measured in PS microwell format, the whole characterization being done within 30 min. Performances of this new colorimetric-based method are detailed. The ADECA method is further demonstrated to be useful for the characterization of aminated polypropylene and glass materials with various sizes and shapes. [Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
155. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells
- Author
-
Moreau, Thomas, Bardin, Florence, Imbert, Jean, Chabannon, Christian, and Tonnelle, Cécile
- Subjects
- *
TRANSGENE expression , *LYMPHOID tissue , *LENTIVIRUSES , *B cells - Abstract
Development of gene transfer strategies will necessitate improved efficiency and control of transduction and transgene expression. We here provide evidence that targeting expression of the GFP reporter gene to the B-lymphoid progeny of genetically modified human hematopoietic progenitor cells can be achieved through the insertion of regulatory sequences from the human CD19 gene promoter into a lentiviral vector. Based on a bioinformatics approach, three human CD19-derived sequences were designed and inserted into a self-inactivated lentiviral vector backbone upstream of the GFP gene: S.CD19 (230 bp), M.CD19 (464 bp), and L.CD19 (1274 bp). These new lentiviral vectors efficiently transduced cord blood CD34+ cells. The M.CD19 and especially L.CD19 sequences preferentially targeted GFP expression to in vitro and in vivo differentiated CD19+ progeny; moreover, transgene expression was detected from the CD34+ pro/pre-B cell to the mature peripheral IgM+ B cell stage. In contrast, GFP expression was weak or absent in primary T-lymphoid and uncommitted progenitor cells or in erythroid, natural killer, or myeloid differentiated cells. Such B-lineage-specific lentiviral vectors may be useful for correcting inherited disorders that affect B-lymphoid cells or for deciphering the transcriptional program that controls B cell commitment and differentiation. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
156. Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
- Author
-
Moreau, Thomas, Calmels, Boris, Barlogis, Vincent, Michel, Gerard, Tonnelle, Cecile, and Chabannon, Christian
- Abstract
X-linked agammaglobulinemia (XLA), or Brutons disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Brutons tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80s, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist despite treatment, and lead to handicapping and further to morbid clinical complications for XLA individuals. Development of gene therapy by transfer of the BTK gene into hematopoietic progenitors could represent an alternative strategy for the treatment of Brutons disease, with the advantage of a definitive cure for XLA patients. Gene therapy of XLA could be considered as a paradigm for future expansion of gene therapy approaches for many other diseases, since future utilization may be strictly dependent on a marked improvement of risk-benefit ratio compared to pre-existing treatments.
- Published
- 2007
157. Defensive Publication of an Advanced Domain Specific Language interpreter with a dynamic extension mechanism.
- Author
-
Moreau, Thomas
- Abstract
A research disclosure is presented which describes a mechanism for advanced Domain Specific Language (DSL) interpreter, used in a Java environment, providing a dynamic extension mechanism allowing to adapt and/or extend its specific and restricted syntax at runtime.
- Published
- 2015
158. CLINICAL WATCH. Age-based screening recommendations for hepatitis C virus infection.
- Author
-
Emerson, Susan A., Moreau, Thomas, Boissonneault, Gilbert, Essary, Alison C., Léger, Marie-Michèle, Ogunfiditimi, Folusho, and Brenneman, Anthony E.
- Subjects
HEPATITIS C risk factors ,PREVENTION of infectious disease transmission ,GENES ,HEPATITIS C ,MEDICAL screening - Published
- 2013
- Full Text
- View/download PDF
159. Inhibition of profibrotic microRNA-21 affects platelets and their releasate
- Author
-
Barwari, Temo, Eminaga, Seda, Mayr, Ursula, Lu, Ruifang, Armstrong, Paul C, Chan, Melissa V, Sahraei, Mahnaz, Fernández-Fuertes, Marta, Moreau, Thomas, Barallobre-Barreiro, Javier, Lynch, Marc, Yin, Xiaoke, Schulte, Christian, Baig, Ferheen, Pechlaner, Raimund, Langley, Sarah R, Zampetaki, Anna, Santer, Peter, Weger, Martin, Plasenzotti, Roberto, Schosserer, Markus, Grillari, Johannes, Kiechl, Stefan, Willeit, Johann, Shah, Ajay M, Ghevaert, Cedric, Warner, Timothy D, Fernández-Hernando, Carlos, Suárez, Yajaira, and Mayr, Manuel
- Subjects
Platelets ,Blood Platelets ,Male ,Proteomics ,RNA, Untranslated ,Noncoding RNAs ,Cardiology ,Transforming Growth Factor beta1 ,Mice ,Animals ,Humans ,Prospective Studies ,Aged ,Aged, 80 and over ,Clinical Trials as Topic ,Myocardium ,Cell Biology ,Fibroblasts ,Middle Aged ,Fibrosis ,3. Good health ,Extracellular Matrix ,Mice, Inbred C57BL ,MicroRNAs ,Female ,Wiskott-Aldrich Syndrome Protein - Abstract
Fibrosis is a major contributor to organ disease for which no specific therapy is available. MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate fibrosis using a proteomics approach. Transfection of miR-21 mimic or inhibitor in murine cardiac fibroblasts revealed limited effects on extracellular matrix (ECM) protein secretion. Similarly, miR-21-null mouse hearts showed an unaltered ECM composition. Thus, we searched for additional explanations as to how miR-21 might regulate fibrosis. In plasma samples from the community-based Bruneck Study, we found a marked correlation of miR-21 levels with several platelet-derived profibrotic factors, including TGF-β1. Pharmacological miR-21 inhibition with an antagomiR reduced the platelet release of TGF-β1 in mice. Mechanistically, Wiskott-Aldrich syndrome protein, a negative regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-21. miR-21-null mice had lower platelet and leukocyte counts compared with littermate controls but higher megakaryocyte numbers in the bone marrow. Thus, to our knowledge this study reports a previously unrecognized effect of miR-21 inhibition on platelets. The effect of antagomiR-21 treatment on platelet TGF-β1 release, in particular, may contribute to the antifibrotic effects of miR-21 inhibitors.
160. Differentiation of Human Pluripotent Stem Cells to Megakaryocytes by Transcription Factor-Driven Forward Programming
- Author
-
Moreau, Thomas, Evans, Amanda L, and Ghevaert, Cedric JG
- Subjects
0301 basic medicine ,Pluripotent Stem Cells ,Forward programming ,Cell Differentiation ,Fibroblasts ,Transfusion medicine ,03 medical and health sciences ,030104 developmental biology ,Transcription factors ,Animals ,Humans ,Human pluripotent stem cells ,Megakaryocytes ,Embryoid Bodies ,Skin - Abstract
The differentiation of megakaryocytes from human pluripotent stem cells in vitro offers intriguing new perspectives for research and transfusion medicine. However, applications have been hampered by the low efficiency of cytokine driven differentiation protocols leading to poor megakaryocyte purity and yield. Here we describe a novel forward programming approach relying on the combined ectopic expression of the three transcription factors GATA1, FLI1, and TAL1 in human pluripotent stem cells for large scale production of mature megakaryocytes using chemically defined culture and minimum cytokines.
161. Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision
- Author
-
Dalby, Amanda, Ballester-Beltrán, Jose, Lincetto, Chiara, Mueller, Annett, Foad, Nicola, Evans, Amanda, Baye, James, Turro, Ernest, Moreau, Thomas, Tijssen, Marloes R, and Ghevaert, Cedric
- Subjects
Pluripotent Stem Cells ,Proto-Oncogene Protein c-fli-1 ,Cell Differentiation ,3. Good health ,megakaryocyte ,Erythroid Cells ,Thrombopoietin ,hemic and lymphatic diseases ,Cytokines ,Humans ,Cell Lineage ,GATA1 Transcription Factor ,Gene Silencing ,Transgenes ,forward programming ,lineage fate decision ,Erythropoietin ,Megakaryocytes ,Cells, Cultured ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,erythroblast - Abstract
The production of blood cells and their precursors from human pluripotent stem cells (hPSCs) in vitro has the potential to make a significant impact upon healthcare provision. We demonstrate that the forward programming of hPSCs through overexpression of GATA1, FLI1, and TAL1 leads to the production of a population of progenitors that can differentiate into megakaryocyte or erythroblasts. Using "rainbow" lentiviral vectors to quantify individual transgene expression in single cells, we demonstrate that the cell fate decision toward an erythroblast or megakaryocyte is dictated by the level of FLI1 expression and is independent of culture conditions. Early FLI1 expression is critical to confer proliferative potential to programmed cells while its subsequent silencing or maintenance dictates an erythroid or megakaryocytic fate, respectively. These committed progenitors subsequently expand and mature into megakaryocytes or erythroblasts in response to thrombopoietin or erythropoietin. Our results reveal molecular mechanisms underlying hPSC forward programming and novel opportunities for application to transfusion medicine.
162. Corrigendum: Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming.
- Author
-
Moreau, Thomas, Evans, Amanda L., Vasquez, Louella, Tijssen, Marloes R., Yan, Ying, Trotter, Matthew W., Howard, Daniel, Colzani, Maria, Arumugam, Meera, Wu, Wing Han, Dalby, Amanda, Lampela, Riina, Bouet, Guenaelle, Hobbs, Catherine M., Pask, Dean C., Payne, Holly, Ponomaryov, Tatyana, Brill, Alexander, Soranzo, Nicole, and Ouwehand, Willem H.
- Abstract
This corrects the article DOI: 10.1038/ncomms11208 [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
163. Screening for ovarian cancer.
- Author
-
Brenneman, Anthony E., Boissonneault, Gilbert, Essary, Alison C., Léger, Marie-Michèle, Moreau, Thomas, and Ogunfiditimi, Folusho
- Abstract
The article presents questions and answers related to ovarian cancer screening, including the prevalence of ovarian cancer in the U.S., the role of American Cancer Society (ACS) in the promotion of ovarian cancer screening, and symptoms of the disease.
- Published
- 2013
- Full Text
- View/download PDF
164. Disorders triggered by gluten.
- Author
-
Boissonneault, Gilbert, Brenneman, Anthony E., Essary, Alison C., Léger, Marie-Michèle, Moreau, Thomas, and Ogunfiditimi, Folusho
- Abstract
The article discusses the importance of gluten-free diet. It mentions that many Americans suffer from celiac disease (CD), gluten sensitivity or wheat allergy, therefore, a gluten-free diet is important for CD, gluten sensitivity and its related disorders. Gluten is found in all products containing wheat, rye, and barley which are found in many foods in Western nations; people should carefully read the ingredients written on prepared food packets so that they can adhere to a gluten-free diet.
- Published
- 2013
165. RHEUMATOID ARTHRITIS.
- Author
-
Moreau, Thomas
- Abstract
The article discusses the current guidelines for diagnosing and treating rheumatoid arthritis (RA) which is crucial for physician assistants (PAs) for its management. Several drugs have been developed which target the specific steps in the autoimmune cascade in RA. An updated clinical classification system issued by the American College of Rheumatology and the European League against Rheumatism (ACR/EULAR) is stated. The primary care PAs play vital role in team management of patients with RA.
- Published
- 2012
166. HEART FAILURE: An update on current care.
- Author
-
Moreau, Thomas, Essary, Alison C., Boissonneault, Gilbert A., Brenneman, Anthony E., Léaer, Marie-Michèle, and Ogunfiditimi, Folusho E.
- Abstract
The article discusses the management of patients with heart failure (HF). It notes that the management of HF must retard the onset of refractory, end-stage disease, avert acute decompensated heart failure and reduce the incidence of sudden cardiac death (SCD). Also, it mentions that three beta-blockers such as bisoprolol, carvedilol and metoprolol succinate have shown to be effective in reducing mortality from HF.
- Published
- 2011
167. CHILDHOOD OBESITY: Screening and early intervention.
- Author
-
Bolssonneault, Gilbert A., Essary, Alison C., Brenneman, Anthony E., Léger, Marie-Michèle, Moreau, Thomas, and Ogunfiditimi, Folusho E.
- Abstract
The article focuses on the screening and early intervention of childhood obesity. It states that almost 20% of children aged two to 19 years in the U.S. are affected by childhood obesity. It mentions that the U.S. Preventive Services Task Force recommends that assessment of body mass index (BMI) must begin at six years of age. It adds that primary care can perform an essential role for treating overweight and obesity in children. INSET: TAKE-HOME POINTS.
- Published
- 2011
168. Oral health: Caring for primary care patients.
- Author
-
Essary, Alison C., Boissonneault, Gilbert A., Brenneman, Anthony E., Léger, Marie-Michèle, McKinnon, Mark F., Moreau, Thomas, and Ogunfiditimi, Folusho E.
- Published
- 2011
169. Performance-enhancer use and misuse.
- Author
-
Moreau, Thomas, O'Donoghue, Daniel L., Boissonneault, Gilbert A., Brenneman, Anthony E., Essary, Alison C., Heinan, Michelle Lynn, and Léger, Marie-Michèle
- Abstract
The article offers information on the use and misuse of performance-enhancing drugs. According to the American Academy of Pediatrics, performance enhancers benefit sports performance by increasing strength, power, speed, or endurance and improve performance by causing changes in behavior, arousal level, and perception of pain. It emphasizes that physician's assistants (PAs) need to know about performance-enhancing practices to help patients manage abuse.
- Published
- 2010
170. Functional neurological restoration of amputated peripheral nerve using biohybrid regenerative bioelectronics
- Author
-
Amy E. Rochford, Alejandro Carnicer-Lombarte, Malak Kawan, Amy Jin, Sam Hilton, Vincenzo F. Curto, Alexandra L. Rutz, Thomas Moreau, Mark R. N. Kotter, George G. Malliaras, Damiano G. Barone, Rochford, Amy E [0000-0003-0195-8002], Carnicer-Lombarte, Alejandro [0000-0002-5650-4692], Jin, Amy [0000-0001-7396-2639], Curto, Vincenzo F [0000-0002-0571-7903], Rutz, Alexandra L [0000-0002-9382-6623], Moreau, Thomas [0000-0003-1090-6685], Kotter, Mark R N [0000-0001-5145-7199], Malliaras, George G [0000-0002-4582-8501], Barone, Damiano G [0000-0002-0091-385X], and Apollo - University of Cambridge Repository
- Subjects
Neurons ,Multidisciplinary ,Humans ,Animals ,Peripheral Nerves ,Electrodes ,Rats ,Nerve Regeneration - Abstract
The development of neural interfaces with superior biocompatibility and improved tissue integration is vital for treating and restoring neurological functions in the nervous system. A critical factor is to increase the resolution for mapping neuronal inputs onto implants. For this purpose, we have developed a new category of neural interface comprising induced pluripotent stem cell (iPSC)–derived myocytes as biological targets for peripheral nerve inputs that are grafted onto a flexible electrode arrays. We show long-term survival and functional integration of a biohybrid device carrying human iPSC-derived cells with the forearm nerve bundle of freely moving rats, following 4 weeks of implantation. By improving the tissue-electronics interface with an intermediate cell layer, we have demonstrated enhanced resolution and electrical recording in vivo as a first step toward restorative therapies using regenerative bioelectronics.
- Published
- 2023
- Full Text
- View/download PDF
171. CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia
- Author
-
Cavan Bennett, Moyra Lawrence, Jose A. Guerrero, Simon Stritt, Amie K. Waller, Yahui Yan, Richard W. Mifsud, Jose Ballester-Beltrán, Ayesha Baig, Annett Mueller, Louisa Mayer, James Warland, Christopher J. Penkett, Parsa Akbari, Thomas Moreau, Amanda L. Evans, Souradip Mookerjee, Gary J. Hoffman, Kourosh Saeb-Parsy, David J. Adams, Amber L. Couzens, Markus Bender, Wendy N. Erber, Bernhard Nieswandt, Randy J. Read, Cedric Ghevaert, Bennett, Cavan [0000-0002-9796-9381], Lawrence, Moyra [0000-0001-9386-5633], Waller, Amie K [0000-0002-9726-5560], Yan, Yahui [0000-0001-6934-9874], Ballester-Beltrán, Jose [0000-0002-3287-2925], Mayer, Louisa [0000-0003-4905-0669], Warland, James [0000-0003-1060-1865], Penkett, Christopher J [0000-0003-4006-7261], Akbari, Parsa [0000-0001-9210-4760], Moreau, Thomas [0000-0003-1090-6685], Mookerjee, Souradip [0000-0003-4904-1324], Saeb-Parsy, Kourosh [0000-0002-0633-3696], Adams, David J [0000-0001-9490-0306], Couzens, Amber L [0000-0003-0057-6686], Bender, Markus [0000-0002-2381-116X], Erber, Wendy N [0000-0002-1028-9376], Nieswandt, Bernhard [0000-0003-1454-7413], Read, Randy J [0000-0001-8273-0047], Ghevaert, Cedric [0000-0002-9251-0934], and Apollo - University of Cambridge Repository
- Subjects
Blood Platelets ,Platelet Count ,Immunology ,Humans ,Cell Biology ,Hematology ,Receptors, Cytokine ,Megakaryocytes ,Microtubules ,Biochemistry ,Thrombocythemia, Essential ,Thrombopoiesis - Abstract
The process of platelet production has so far been understood to be a 2-stage process: megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation, with each phase regulating the peripheral blood platelet count. Proplatelet formation releases into the bloodstream beads-on-a-string preplatelets, which undergo fission into mature platelets. For the first time, we show that preplatelet maturation is a third, tightly regulated, critical process akin to cytokinesis that regulates platelet count. We show that deficiency in cytokine receptor-like factor 3 (CRLF3) in mice leads to an isolated and sustained 25% to 48% reduction in the platelet count without any effect on other blood cell lineages. We show that Crlf3−/− preplatelets have increased microtubule stability, possibly because of increased microtubule glutamylation via the interaction of CRLF3 with key members of the Hippo pathway. Using a mouse model of JAK2 V617F essential thrombocythemia, we show that a lack of CRLF3 leads to long-term lineage-specific normalization of the platelet count. We thereby postulate that targeting CRLF3 has therapeutic potential for treatment of thrombocythemia.
- Published
- 2022
172. Extraction of Nystagmus Patterns from Eye-Tracker Data with Convolutional Sparse Coding
- Author
-
Laurent Oudre, Matthieu P. Robert, Maxence Rateaux, Thomas Moreau, Clement Lalanne, CB - Centre Borelli - UMR 9010 (CB), Service de Santé des Armées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Ecole Normale Supérieure Paris-Saclay (ENS Paris Saclay)-Université Paris Cité (UPCité), Centre de Mathématiques et de Leurs Applications (CMLA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Traitement et Transport de l'Information (L2TI), Université Sorbonne Paris Nord, Modelling brain structure, function and variability based on high-field MRI data (PARIETAL), Service NEUROSPIN (NEUROSPIN), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Service de Santé des Armées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Ecole Normale Supérieure Paris-Saclay (ENS Paris Saclay)-Université de Paris (UP), Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, and Moreau, Thomas
- Subjects
Signal Processing (eess.SP) ,FOS: Computer and information sciences ,Computer Science - Machine Learning ,Eye Movements ,genetic structures ,Computer science ,[INFO.INFO-TS] Computer Science [cs]/Signal and Image Processing ,Movement ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,02 engineering and technology ,Nystagmus ,010501 environmental sciences ,01 natural sciences ,Motion (physics) ,Nystagmus, Pathologic ,Machine Learning (cs.LG) ,[MATH.MATH-GM]Mathematics [math]/General Mathematics [math.GM] ,[INFO.INFO-LG]Computer Science [cs]/Machine Learning [cs.LG] ,[INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing ,0202 electrical engineering, electronic engineering, information engineering ,medicine ,FOS: Electrical engineering, electronic engineering, information engineering ,Humans ,Electrical Engineering and Systems Science - Signal Processing ,0105 earth and related environmental sciences ,Blinking ,business.industry ,Movement (music) ,Eye movement ,Pattern recognition ,[MATH.MATH-GM] Mathematics [math]/General Mathematics [math.GM] ,[INFO.INFO-LG] Computer Science [cs]/Machine Learning [cs.LG] ,eye diseases ,Eye tracking ,020201 artificial intelligence & image processing ,Artificial intelligence ,sense organs ,medicine.symptom ,Eye blink ,business ,Neural coding ,Algorithms - Abstract
International audience; The analysis of the Nystagmus waveforms from eye-tracking records is crucial for the clinicial interpretation of this pathological movement. A major issue to automatize this analysis is the presence of natural eye movements and eye blink artefacts that are mixed with the signal of interest. We propose a method based on Convolutional Dictionary Learning that is able to automaticcaly highlight the Nystagmus waveforms, separating the natural motion from the pathological movements. We show on simulated signals that our method can indeed improve the pattern recovery rate and provide clinical examples to illustrate how this algorithm performs.
- Published
- 2020
173. Inhibition of Pro-Fibrotic MicroRNA-21 Affects Platelets and their Releasate
- Author
-
Carlos Fernández-Hernando, Yajaira Suárez, Javier Barallobre-Barreiro, Ruifang Lu, Roberto Plasenzotti, Paul C Armstrong, Mahnaz Sahraei, Johann Willeit, Manuel Mayr, Melissa V. Chan, Marc Lynch, Sarah R. Langley, Raimund Pechlaner, Johannes Grillari, Christian Schulte, Ajay M. Shah, Peter Santer, Markus Schosserer, Martin Weger, Timothy D. Warner, Ferheen Baig, Seda Eminaga, Ursula Mayr, Xiaoke Yin, Marta Fernández-Fuertes, Anna Zampetaki, Thomas Moreau, Cedric Ghevaert, Temo Barwari, Stefan Kiechl, Moreau, Thomas [0000-0003-1090-6685], Ghevaert, Cedric [0000-0002-9251-0934], and Apollo - University of Cambridge Repository
- Subjects
Blood Platelets ,Male ,Proteomics ,Platelets ,0301 basic medicine ,RNA, Untranslated ,Noncoding RNAs ,Cardiology ,Pharmacology ,Transforming Growth Factor beta1 ,Extracellular matrix ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Megakaryocyte ,Fibrosis ,medicine ,Animals ,Humans ,Platelet ,Antagomir ,Secretion ,Prospective Studies ,Aged ,Aged, 80 and over ,Clinical Trials as Topic ,business.industry ,Myocardium ,Cell Biology ,General Medicine ,Transfection ,Fibroblasts ,Middle Aged ,medicine.disease ,Extracellular Matrix ,3. Good health ,Mice, Inbred C57BL ,MicroRNAs ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Female ,Bone marrow ,business ,Wiskott-Aldrich Syndrome Protein ,Research Article - Abstract
Fibrosis is a major contributor to organ disease for which no specific therapy is available. MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate fibrosis using a proteomics approach. Transfection of miR-21 mimic or inhibitor in murine cardiac fibroblasts revealed limited effects on extracellular matrix (ECM) protein secretion. Similarly, miR-21–null mouse hearts showed an unaltered ECM composition. Thus, we searched for additional explanations as to how miR-21 might regulate fibrosis. In plasma samples from the community-based Bruneck Study, we found a marked correlation of miR-21 levels with several platelet-derived profibrotic factors, including TGF-β1. Pharmacological miR-21 inhibition with an antagomiR reduced the platelet release of TGF-β1 in mice. Mechanistically, Wiskott-Aldrich syndrome protein, a negative regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-21. miR-21–null mice had lower platelet and leukocyte counts compared with littermate controls but higher megakaryocyte numbers in the bone marrow. Thus, to our knowledge this study reports a previously unrecognized effect of miR-21 inhibition on platelets. The effect of antagomiR-21 treatment on platelet TGF-β1 release, in particular, may contribute to the antifibrotic effects of miR-21 inhibitors., MicroRNA-21 inhibition may convey its therapeutic benefits in fibrosis through its action in bone marrow cells rather than targeting fibroblasts directly.
- Published
- 2018
174. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
- Author
-
Gwladys Zabouo, Anne-Marie Imbert, Jocelyne Jacquemier, Benjamin Esterni, Pascal Finetti, François Bertucci, Christian Chabannon, Thomas Moreau, Daniel Birnbaum, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM / U891 Inserm), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC - Biotherapie - Marseille, Institut National de la Santé et de la Recherche Médicale (INSERM), Moreau, Thomas [0000-0003-1090-6685], Apollo - University of Cambridge Repository, and Bertucci, François
- Subjects
CA15-3 ,Adult ,Vimentin ,Breast Neoplasms ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,CD146 Antigen ,Biology ,Metastasis ,Immunoenzyme Techniques ,Mesoderm ,Young Adult ,Breast cancer ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Cell Movement ,medicine ,Tumor Cells, Cultured ,Humans ,Epithelial–mesenchymal transition ,Gene Silencing ,RNA, Messenger ,RNA, Small Interfering ,Aged ,Oligonucleotide Array Sequence Analysis ,Medicine(all) ,Aged, 80 and over ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Middle Aged ,medicine.disease ,Flow Cytometry ,Prognosis ,Gene Expression Regulation, Neoplastic ,Tissue Array Analysis ,Cancer cell ,biology.protein ,Cancer research ,CD146 ,Female ,Ovarian cancer ,Research Article - Abstract
International audience; Introduction: Metastasis is a complex process involving loss of adhesion, migration, invasion and proliferation of cancer cells. Cell adhesion molecules play a pivotal role in this phenomenon by regulating cell-cell and cell-matrix interactions. CD146 (MCAM) is associated with an advanced tumor stage in melanoma, prostate cancer and ovarian cancer. Studies of CD146 expression and function in breast cancer remain scarce except for a report concluding that CD146 could act as a tumor suppressor in breast carcinogenesis.Methods: To resolve these apparent discrepancies in the role of CD146 in tumor cells, we looked at the association of CD146 expression with histoclinical features in human primary breast cancers using DNA and tissue microarrays. By flow cytometry, we characterized CD146 expression on different breast cancer cell lines. Using siRNA or shRNA technology, we studied functional consequences of CD146 downmodulation of MDA-MB-231 cells in migration assays. Wild-type, mock-transfected and downmodulated transfected cells were profiled using whole-genome DNA microarrays to identify genes whose expression was modified by CD146 downregulation.Results: Microarray studies revealed the association of higher levels of CD146 with histoclinical features that belong to the basal cluster of human tumors. Expression of CD146 protein on epithelial cells was detected in a small subset of cancers with histoclinical features of basal tumors. CD146+ cell lines displayed a mesenchymal phenotype. Downmodulation of CD146 expression in the MDA-MB-231 cell line resulted in downmodulation of vimentin, as well as of a set of genes that include both genes associated with a poor prognosis in a variety of cancers and genes known to promote cell motility. In vitro functional assays revealed decreased migration abilities associated with decreased CD146 expression.Conclusions: In addition to its expression in the vascular compartment, CD146 is expressed on a subset of epithelial cells in malignant breast. CD146 may directly or indirectly contribute to tumor aggressiveness by promoting malignant cell motility. Changes in molecular signatures following downmodulation of CD146 expression suggest that CD146 downmodulation is associated with the reversal of several biological characteristics associated with epithelial to mesenchymal transition, and the phenomenon associated with the metastatic process.
- Published
- 2009
175. Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study.
- Author
-
Benderra MA, Aparicio A, Leblanc J, Wassermann D, Kempf E, Galula G, Bernaux M, Canellas A, Moreau T, Bellamine A, Spano JP, Daniel C, Champ J, Canouï-Poitrine F, Gligorov J, On Behalf Of The Ap-Hp/Universities/Inserm Covid-Research Collaboration, Cancer Ap-Hp Group Covid-Task Force, and Ap-Hp Covid Cdw Initiative Acci
- Abstract
Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate., Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis., Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07-1.81]), advanced age (78-86 y: aHR = 2.83 [95% CI: 1.78-4.51] vs. <66 y; 86-103 y: aHR = 2.61 [95% CI: 1.56-4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41-3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70-2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08-4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02-2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50-0.84])., Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome.
- Published
- 2021
- Full Text
- View/download PDF
176. Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults.
- Author
-
Diedisheim M, Dancoisne E, Gautier JF, Larger E, Cosson E, Fève B, Chanson P, Czernichow S, Tatulashvili S, Raffin-Sanson ML, Sallah K, Bourgeon M, Ajzenberg C, Hartemann A, Daniel C, Moreau T, Roussel R, and Potier L
- Subjects
- Aged, Aged, 80 and over, COVID-19 virology, Female, France epidemiology, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, COVID-19 epidemiology, Diabetes Mellitus physiopathology, Hospital Mortality trends, Hospitalization statistics & numerical data, SARS-CoV-2 isolation & purification, Severity of Illness Index
- Abstract
Context: Diabetes is reported as a risk factor for severe coronavirus disease 2019 (COVID-19), but whether this risk is similar in all categories of age remains unclear., Objective: To investigate the risk of severe COVID-19 outcomes in hospitalized patients with and without diabetes according to age categories., Design Setting and Participants: We conducted a retrospective observational cohort study of 6314 consecutive patients hospitalized for COVID-19 between February and 30 June 2020 in the Paris metropolitan area, France; follow-up was recorded until 30 September 2020., Main Outcome Measure(s): The main outcome was a composite outcome of mortality and orotracheal intubation in subjects with diabetes compared with subjects without diabetes, after adjustment for confounding variables and according to age categories., Results: Diabetes was recorded in 39% of subjects. Main outcome was higher in patients with diabetes, independently of confounding variables (hazard ratio [HR] 1.13 [1.03-1.24]) and increased with age in individuals without diabetes, from 23% for those <50 to 35% for those >80 years but reached a plateau after 70 years in those with diabetes. In direct comparison between patients with and without diabetes, diabetes-associated risk was inversely proportional to age, highest in <50 years and similar after 70 years. Similarly, mortality was higher in patients with diabetes (26%) than in those without diabetes (22%, P < 0.001), but adjusted HR for diabetes was significant only in patients younger than age 50 years (HR 1.81 [1.14-2.87])., Conclusions: Diabetes should be considered as an independent risk factor for the severity of COVID-19 in young adults more so than in older adults, especially for individuals younger than 70 years., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
177. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium.
- Author
-
Brat GA, Weber GM, Gehlenborg N, Avillach P, Palmer NP, Chiovato L, Cimino J, Waitman LR, Omenn GS, Malovini A, Moore JH, Beaulieu-Jones BK, Tibollo V, Murphy SN, Yi SL, Keller MS, Bellazzi R, Hanauer DA, Serret-Larmande A, Gutierrez-Sacristan A, Holmes JJ, Bell DS, Mandl KD, Follett RW, Klann JG, Murad DA, Scudeller L, Bucalo M, Kirchoff K, Craig J, Obeid J, Jouhet V, Griffier R, Cossin S, Moal B, Patel LP, Bellasi A, Prokosch HU, Kraska D, Sliz P, Tan ALM, Ngiam KY, Zambelli A, Mowery DL, Schiver E, Devkota B, Bradford RL, Daniar M, Daniel C, Benoit V, Bey R, Paris N, Serre P, Orlova N, Dubiel J, Hilka M, Jannot AS, Breant S, Leblanc J, Griffon N, Burgun A, Bernaux M, Sandrin A, Salamanca E, Cormont S, Ganslandt T, Gradinger T, Champ J, Boeker M, Martel P, Esteve L, Gramfort A, Grisel O, Leprovost D, Moreau T, Varoquaux G, Vie JJ, Wassermann D, Mensch A, Caucheteux C, Haverkamp C, Lemaitre G, Bosari S, Krantz ID, South A, Cai T, and Kohane IS
- Abstract
We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across five countries (www.covidclinical.net). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions., Competing Interests: Competing interestsR.B. and A.M. are shareholders of Biomeris s.r.l., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
178. Extraction of Nystagmus Patterns from Eye-Tracker Data with Convolutional Sparse Coding.
- Author
-
Lalanne C, Rateaux M, Oudre L, Robert MP, and Moreau T
- Subjects
- Algorithms, Blinking, Eye Movements, Humans, Movement, Nystagmus, Pathologic
- Abstract
The analysis of the Nystagmus waveforms from eye-tracking records is crucial for the clinical interpretation of this pathological movement. A major issue to automatize this analysis is the presence of natural eye movements and eye blink artefacts that are mixed with the signal of interest. We propose a method based on Convolutional Dictionary Learning that is able to automatically highlight the Nystagmus waveforms, separating the natural motion from the pathological movements. We show on simulated signals that our method can indeed improve the pattern recovery rate and provide clinical examples to illustrate how this algorithm performs.
- Published
- 2020
- Full Text
- View/download PDF
179. Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity.
- Author
-
Shepherd JH, Howard D, Waller AK, Foster HR, Mueller A, Moreau T, Evans AL, Arumugam M, Bouët Chalon G, Vriend E, Davidenko N, Ghevaert C, Best SM, and Cameron RE
- Subjects
- Biocompatible Materials chemistry, Bioreactors, Cell Culture Techniques instrumentation, Cell Culture Techniques methods, Cells, Cultured, Equipment Design, Humans, Blood Platelets cytology, Collagen chemistry, Megakaryocytes cytology, Pluripotent Stem Cells cytology, Thrombopoiesis, Tissue Scaffolds chemistry
- Abstract
Platelet transfusions are a key treatment option for a range of life threatening conditions including cancer, chemotherapy and surgery. Efficient ex vivo systems to generate donor independent platelets in clinically relevant numbers could provide a useful substitute. Large quantities of megakaryocytes (MKs) can be produced from human pluripotent stem cells, but in 2D culture the ratio of platelets harvested from MK cells has been limited and restricts production rate. The development of biomaterial cell supports that replicate vital hematopoietic micro-environment cues are one strategy that may increase in vitro platelet production rates from iPS derived Megakaryocyte cells. In this paper, we present the results obtained generating, simulating and using a novel structurally-graded collagen scaffold within a flow bioreactor system seeded with programmed stem cells. Theoretical analysis of porosity using micro-computed tomography analysis and synthetic micro-particle filtration provided a predictive tool to tailor cell distribution throughout the material. When used with MK programmed stem cells the graded scaffolds influenced cell location while maintaining the ability to continuously release metabolically active CD41
+ CD42+ functional platelets. This scaffold design and novel fabrication technique offers a significant advance in understanding the influence of scaffold architectures on cell seeding, retention and platelet production., (Copyright © 2018. Published by Elsevier Ltd.)- Published
- 2018
- Full Text
- View/download PDF
180. Differentiation of Human Pluripotent Stem Cells to Megakaryocytes by Transcription Factor-Driven Forward Programming.
- Author
-
Moreau T, Evans AL, and Ghevaert CJG
- Subjects
- Animals, Cell Differentiation, Embryoid Bodies cytology, Fibroblasts cytology, Fibroblasts metabolism, Humans, Megakaryocytes metabolism, Pluripotent Stem Cells metabolism, Skin cytology, Megakaryocytes cytology, Pluripotent Stem Cells cytology, Transcription Factors metabolism
- Abstract
The differentiation of megakaryocytes from human pluripotent stem cells in vitro offers intriguing new perspectives for research and transfusion medicine. However, applications have been hampered by the low efficiency of cytokine driven differentiation protocols leading to poor megakaryocyte purity and yield. Here we describe a novel forward programming approach relying on the combined ectopic expression of the three transcription factors GATA1, FLI1, and TAL1 in human pluripotent stem cells for large scale production of mature megakaryocytes using chemically defined culture and minimum cytokines.
- Published
- 2018
- Full Text
- View/download PDF
181. Age-based screening recommendations for hepatitis C virus infection.
- Author
-
Emerson SA and Moreau T
- Subjects
- Age Factors, Hepatitis C drug therapy, Humans, Mass Screening, Practice Guidelines as Topic, Risk Factors, Serologic Tests, United States, Hepatitis C diagnosis
- Published
- 2013
- Full Text
- View/download PDF
182. Rheumatoid arthritis: classification and treatment.
- Author
-
Moreau T
- Subjects
- Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid etiology, HLA-DR1 Antigen immunology, HLA-DR4 Antigen immunology, Humans, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid classification, Arthritis, Rheumatoid drug therapy
- Published
- 2012
183. Heart failure: an update on current care.
- Author
-
Moreau T
- Subjects
- Heart Failure diagnosis, Heart Failure etiology, Humans, Heart Failure therapy
- Published
- 2011
184. CT scans and radiation exposure.
- Author
-
Brenneman AE, Essary AC, Boissonneault GA, Léger MM, McKinnon MF, Moreau T, and Ogunfiditimi FE
- Subjects
- Humans, Pelvis diagnostic imaging, Radiation Dosage, Radiography, Abdominal, Tomography, X-Ray Computed adverse effects
- Published
- 2011
185. Concussion: assessment of traumatic brain injuries.
- Author
-
Moreau T
- Subjects
- Brain Concussion physiopathology, Humans, Bed Rest, Brain Concussion diagnosis, Brain Concussion therapy, Glasgow Coma Scale
- Published
- 2010
- Full Text
- View/download PDF
186. Hypertension. Is BP out of control or uncontrolled?
- Author
-
Essary AC, Boissonneault GA, Brenneman AE, Léger MM, McKinnon MF, Moreau T, and Ogunfiditimi FE
- Subjects
- Blood Pressure Monitoring, Ambulatory, Health Behavior, Humans, Hypertension epidemiology, Practice Guidelines as Topic, Hypertension prevention & control
- Published
- 2010
187. Substance abuse: performance-enhancer use and misuse.
- Author
-
Moreau T
- Subjects
- Adolescent, Adult, Central Nervous System Agents adverse effects, Child, Humans, Doping in Sports statistics & numerical data, Substance-Related Disorders diagnosis, Substance-Related Disorders epidemiology, Substance-Related Disorders therapy
- Published
- 2010
188. Major depression. Screening and treatment.
- Author
-
O'Donoghue DL, Boissonneault GA, Brenneman AE, Essary AC, Fortier F, Heinan ML, Léger MM, McNellis R, Moreau T, and Zarbock S
- Subjects
- Antidepressive Agents therapeutic use, Chronic Disease, Depressive Disorder, Major drug therapy, Humans, Risk Factors, Depressive Disorder, Major diagnosis, Mass Screening
- Published
- 2009
189. The PCMH: a model for primary care.
- Author
-
Essary AC, O'Donoghue DL, Boissonneault GA, Brenneman AE, Heinan ML, Moreau T, and Zarbock S
- Subjects
- Continuity of Patient Care, Health Services Accessibility, Humans, Patient-Centered Care economics, Primary Health Care economics, Quality Assurance, Health Care, United States, Models, Organizational, Patient-Centered Care organization & administration, Primary Health Care methods
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.